Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

TwitterFacebookLinkedInYouTube
People Strong - Innovation Driven

News


BWXT Announces Availability of FDA-Approved Indium In-111 Oxyquinoline Solution

25 September 2019

(LYNCHBURG, Va. – September 26, 2019) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT ITG Canada, Inc., having received approval from the U.S. Food and Drug Administration (FDA) on its abbreviated new drug application for its generic version of Indium In-111 Oxyquinoline Solution, is now making the product available for sale in the United States.

Archive

Tags

Press Contacts:

BWX Technologies, Inc.

Jud Simmons 
+1 434.522.3800
hjsimmons@bwxt.com

BWXT Canada Ltd.  

Natalie Cutler 
+1 519.620.5288 
nacutler@bwxt.com 

BWXT Nuclear Energy Canada Inc.

Natalie Cutler
+1 519.620.5288  
nacutler@bwxt.com 

Nuclear Fuel Services, Inc.

Laura Bailey 
+1 423.743.9141
lebailey@nuclearfuelservices.com